Professor Nick Lemoine
Director, CRUK Barts Centre; Medical Director, NIHR Clinical Research Network
I am the Director of Barts Cancer Institute. My groups’ primary research interests are in the genomics and molecular pathology of pancreatic cancer and the development of oncolytic virotherapy.
Professor Fran Balkwill
Professor of Cancer Biology
My key area of interest is in cancer and the tumour microenvironment, especially in ovarian cancer. I study the links between cancer and inflammation and research ways of translating this to clinical trials.
Professor Stephen Duffy
Professor of Cancer Screening
My research activities are concentrated on cancer screening and early diagnosis. There is potential for considerable saving of lives from cancer if it were diagnosed at an earlier stage.
Professor Jude Fitzgibbon
Professor of Personalised Cancer Medicine
My research group works on molecular pathology, genetics and progression of leukaemia and lymphomas, aiming to improve on current diagnostic, prognostic and treatment strategies.
Professor Trevor Graham
Professor of Cancer Evolution
My lab measures the patterns of clonal evolution that define carcinogenesis and develops novel mathematical tools for analysis and prediction. By characterising tumour evolution, we aim to find better ways to determine prognosis and more effective ways to treat cancers.
Professor Kairbaan Hodivala-Dilke
Deputy Institute Director, Professor of the Tumour Microenvironment
Cancers are composed of both tumour and stromal compartments. We are interested in understanding the molecular basis of how the tumour stroma contributes to tumour growth, therapy resistance and spread, in various solid tumours including lung cancers, pancreatic cancer and melanoma.
Professor Hemant Kocher
Professor of Liver and Pancreas Surgery
My clinical research interests include tissue banking, clinical trials, innovative surgical techniques, epidemiology, meta-analysis and patient care pathways. My translational research interests include pancreatic cancer stroma and tumour-stroma cross-talk including cell signalling, adhesion, metastasis and invasion.
Professor Ranjit Manchanda
Consultant Gynaecological Oncologist, Professor of Gynaecological Oncology
My main research focus is based on the development of population based approaches to genetic testing for risk stratification, cancer prevention and using targeted surgical approaches for cancer prevention in gynaecological cancers.
Professor John F. Marshall
Professor of Tumour Biology
For over 25 years I have studied the biology of tumour invasion with a particular interest in the roles of the adhesion molecules expressed on the cell surface that mediate this process. Our group concentrates on the study of integrins that are the principal family of adhesion molecules that mediate interaction between cells and the extracellular matrix (ECM).
Professor Tyson V. Sharp
Professor of Cellular and Molecular Biology
My group’s work focuses on the role of the tumour suppressor protein LIMD1 and its family members Ajuba and WTIP and how their deregulation in normal tissue contributes to the development of lung, renal and breast cancer.
Dr Katiuscia Bianchi
Senior Lecturer
I am interested in all the strategies cancer cells adopt to proliferate and evade cell death, in order to develop new therapeutic strategies. Specifically, my research focuses on how cancer cell metabolism affects tumour growth and investigating how inflammation can drive malignant transformation.
Dr Andrejs Braun
Senior Lecturer
I am interested in the mechanisms of tumour clearance in response to targeted therapy with monoclonal antibodies. I work on antibody therapies for lymphoma and the epigenetics of somatic hypermutation in normal and malignant B cells.
Dr Angus James Cameron
Senior Lecturer
My research focuses on kinases regulating cancer cell growth and motility to understand how and when to target them with drugs. My group is currently examining the role of the PKN kinases in malignant progression.
Professor Claude Chelala
Co-Director, Centre for Computational Biology, LSI; Professor of Bioinformatics
My research interests lie in the area of translational bioinformatics. Current research projects are focused in high-throughput data analysis, integration with clinical data, databases and software development, particularly for pancreatic cancer and breast cancer.
Professor Tatjana Crnogorac-Jurcevic
Professor of Molecular Pathology and Biomarkers
My research focuses on molecular pathology of pancreatic cancer, in particular its development and progression. We are using this knowledge to develop biomarkers for early, non-invasive detection of this malignancy in urine specimens.
Dr Pedro R. Cutillas
Reader in Cell Signalling and Proteomics
My research group uses unique proteomics and computational approaches to understand how cell signalling pathways driven by the activity of protein kinases contribute to the development of cancer. Increasing this knowledge will be invaluable in advancing personalised cancer therapies.
Dr Jeff Davies
Reader in Haemato-oncology and Honorary Consultant
My group works on developing novel approaches to improve efficacy and safety of allogeneic stem cell transplantation and adoptive immunotherapy as treatments for blood cancers. We focus on T-cell alloreactivity in the context of stem cell transplantation and immunotherapy.
Dr Gabriella Ficz
Senior Lecturer
My group aims to discover the epigenetic changes taking place during cancer initiation and develop potential drugs that can prevent these changes which may be abnormal but reversible, before many damaging mutations occur.
Dr Andy Finch
Senior Lecturer
Our group studies changes in metabolism and metabolic stresses that are caused by oncogene activation and how these stresses lead to tumour suppressive responses.
Dr Paolo Gallipoli
Clinical Senior Lecturer in Haemato-Oncology
My research interests focus on mechanisms of disease initiation and maintenance and the identification and validation of novel therapeutic targets in myeloid leukaemias.
Dr Susana Godinho
Senior Lecturer
Our research group focuses on understanding how centrosome amplification impacts tumour progression and how we can target cells with amplified centrosomes to develop new cancer therapies.
Professor John Gribben
Professor of Medical Oncology
My group focuses on immunological approaches to the treatment of haematological cancers. My primary research interests include the immunotherapy of cancer (including stem cell transplantation), the identification of B-cell-tumour antigens; and the detection and treatment of minimal residual disease in leukaemia and lymphoma.
Professor Richard Grose
Professor of Cancer Cell Biology
We are interested in how cancer cells interact with each other and the microenvironment. We investigate how cancer cells develop resistance to therapies and design drug combination approaches to overcome this.
Dr Gunnel Halldén
Reader in Cancer Gene Therapy
The research in our team is focused on the development of novel treatment strategies to target prostate and pancreatic cancers using genetically modified viruses that target, replicate and kill cancer cells but leave normal cells unharmed.
Dr Zuzana Horejsi
Lecturer
My lab focuses on discovering functions of phosphorylation induced by damaged DNA in normal and cancer cells, and investigating the role of different phosphorylation events in cancer development.
Dr Li Jia
Senior Lecturer
I am interested in studying the effects of the inflammatory microenvironment on disease progression and resistance to treatment in haematological malignancies with emphasis on survival and mechanisms of treatment resistance in chronic lymphocytic leukaemia and B cell lymphoma.
Professor Louise Jones
Professor of Breast Pathology
My research in breast cancer focuses on the progression of in-situ to invasive disease with the aims of identifying markers which can predict behaviour and novel therapeutic targets.
Dr Stéphanie Kermorgant
Reader in Cellular Oncology
We study the role of growth factor receptor signalling and intracellular trafficking (movement inside cells) in tumour growth and metastasis in the view of improving cancer therapy.
Professor Kamil R. Kranc
Clinical Professor of Haematology
Our research aims to understand the biology of leukaemia stem cells and identify tricks they use to escape treatments. My group employs multidisciplinary approaches to understand how HSCs chose to self-renew or differentiate and how these cell fate decisions are affected under pathological conditions to generate leukaemic stem cells.
Dr Sergey Krysov
Senior Lecturer
My studies concentrate on the immunogenetics of human B cell malignancies, such as chronic lymphocytic leukaemia, follicular lymphoma and the role for B cell receptor in the development of B cell lymphoma and leukaemia.
Dr Rifca Le Dieu
Clinical Senior Lecturer
I am the Module Lead for 3 undergraduate Biomedical Science Modules. I am also the Cancer Theme Lead for MBBS with direct responsibility for Year 2 Cancer Week. In addition, I supervise MSc project dissertations.
Dr Michelle Lockley
Reader in Medical Oncology, Honorary Consultant
Our lab aims to improve treatments for women with ovarian cancer, particularly those that are resistant to chemotherapy. We are interested in developing therapies that can adapt to the evolution of chemotherapy resistance over time.
Dr Daniela Loessner
Reader in Bioengineering and Cancer
My research interests are to apply tissue-engineered technologies to study the role of the microenvironment in modulating cancer progression and therapy response. I develop 3D models that mimic the human disease and use this to develop novel therapies.
Professor Yong-Jie Lu
Professor of Molecular Oncology
We aim to identify genetic alterations that influence cancer development, progression and therapeutic responses, in particular prostate cancer, and further develop them into biomarkers for cancer diagnosis and therapeutic stratification, with a current focus on circulating biomarkers.
Dr Faraz Mardakheh
Lecturer
My lab utilises state-of-art multi-omics methodologies to study how protein synthesis is dysregulated in cancer cells, and how this dysregulation contributes to various stages of cancer progression.
Dr Sarah Martin
Reader; Director of Graduate Studies for Research (BCI)
Our research is based on exploiting DNA repair defects in cancer for the identification of new personalised therapies. We use compound and siRNA screening to identify new therapeutics for tumours based on their specific DNA repair status.
Dr Sarah McClelland
Senior Lecturer
My lab aims to understand the mechanisms that underlie numerical and structural chromosome aberrations in cancer at a molecular level, which also involves understanding how normal cells replicate and segregate their genomes.
Dr Stuart McDonald
Senior Lecturer
Our main research areas are focused on understanding the evolution of Barrett’s oesophagus to cancer, field cancerisation of the human stomach, and clonal expansion in ductal carcinoma in situ of the human breast.
Dr Jessica Okosun
Clinical Senior Lecturer
My research focuses on understanding the genetic and molecular mechanisms that underlie the initiation and progression of B-cell non-Hodgkin’s lymphomas in order to define clinically-relevant biomarkers.
Dr Oliver M. Pearce
Lecturer
The focus of our research is the tumour microenvironment and we are particularly interested in understanding the composition and function of the tumour extracellular matrix in immunosuppression. Cancer types we focus on include ovarian and breast cancers.
Dr Barrie Peck
Lecturer
My lab aims to understand the alterations in metabolism that take place in cancer and investigate whether extrinsic factors, such as diet, influence cancer metabolism and disease trajectory. We then want to uncover whether these dependencies can be exploited therapeutically.
Professor Thomas Powles
Professor of Genitourinary Oncology, Director, Barts Cancer Centre, Lead for Solid Tumour Research
My main research interests are in genital and urinary cancers, leading a spectrum of clinical studies from phase I to randomised phase III. The majority of the studies are translational phase II studies investigating novel targeted and immune therapies.
Dr David Propper
Senior Lecturer
My focus is detailed translational trials in pancreatic cancer. I work with scientists within the BCI in crosscutting themes targeting the tumour microenvironment, with approaches including immune therapies, stem cell, stromal and vascular targeting.
Dr Prabhakar Rajan
Clinical Senior Lecturer in Urology
My laboratory research explores alternative pre-mRNA splicing in prostate cancer (PCa) biology, transcriptomic changes during PCa treatment, and liquid biopsy molecular biomarkers of treatment outcomes. My clinical research investigates patterns of treatment outcomes for PCa patients.
Dr Paulo Ribeiro
Senior Lecturer
Our research group is interested in uncovering the molecular mechanisms regulating tissue growth, invasion and metastasis using the fruit fly Drosophila melanogaster as a genetically tractable model organism.
Dr John Riches
Clinical Senior Lecturer
My major research interest is understanding the metabolism of chronic lymphocytic leukaemia and lymphoma with the aim that this will underpin the development of the next generation of anti-metabolic drugs for these diseases.
Dr Kevin Rouault-Pierre
Lecturer
My main research interests are in haematopoietic stem cells (HSCs) and leukemic initiating cells. I seek to understand how intrinsic and extrinsic signals are integrated by normal and malignant stem cells.
Professor Victoria Sanz-Moreno
Professor of Cancer Cell Biology
Our research focuses on how the cytoskeleton of cancer cells regulates transcriptional rewiring during tumour growth and dissemination. We aim to understand how such rewiring affects the tumour microenvironment.
Professor Peter Szlosarek
Professor of Medical Oncology
My main research interest is in exploring why ASS1 is aberrantly expressed in human cancers and how this knowledge may be exploited for anticancer therapy. I lead an active translational programme from bench to bedside of the arginine-depleting agent ADI-PEG20 in several hard-to-treat cancers.
Professor Peter Schmid
Professor of Cancer Medicine
My research interests primarily focus on breast cancer, lung cancer and early drug development. I oversee clinical and translational research on immune checkpoint inhibitors and other immune strategies.
Dr Lovorka Stojic
Lecturer
My group studies how RNA-mediated mechanisms, in particular long noncoding RNAs, regulate cell division and how dysregulation of these processes leads to genome instability and cancer.
Dr Jane Sosabowski
Reader in Preclinical Molecular Imaging
My main interests are in radiopharmaceutical development and the use of pre-clinical molecular imaging in drug development, especially biopharmaceuticals. The lab has a long-standing interest in imaging CCK-2 and GRP receptors which are overexpressed in a number of tumour types.
Dr Jun Wang
Senior Lecturer
My main research interests lie in applying bioinformatics and computational approaches to analyse large-scale cancer datasets to uncover novel diagnostic and prognostic features. I also lead the CRUK Barts Centre Bioinformatics Core Facility.
Professor Yaohe Wang
Professor of Cancer Cell and Gene Therapy
We work on cancer prevention and immunotherapy using tumour-targeted replicating oncolytic viruses, in particular focusing on replicating adenovirus and vaccinia virus.
Dr Benjamin Werner
Lecturer
My group combines mathematics, computer simulations and genomic information to study evolutionary processes. We aim to understand how a tumour’s evolutionary history is reflected in its genome, how evolution can be quantified in individual tumours and how this information predicts future evolution.
Dr Bela Wrench
Clinical Senior Lecturer
My research focuses on the fundamental aspects of leukaemia initiating cell (LIC) biology in adult acute lymphoblastic leukaemia, with the aim of gaining fundamental insight into the underlying biology of LICs to reveal dependencies that are tractable targets for therapy.